The COVID-19 Omicron variant has forced the US Food and Drug Administration to pump the brake once again on performing on-site surveillance inspections.
In a small blurb tucked away in a 4 January news roundup from the agency, the FDA explained that it decided on 29 December to put in place “temporary...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?